middle.news
Why Did Imricor’s Revenue Halve While Losses Nearly Doubled in H1 2025?
8:05am on Tuesday 26th of August, 2025 AEST
•
Healthcare
Read Story
Why Did Imricor’s Revenue Halve While Losses Nearly Doubled in H1 2025?
8:05am on Tuesday 26th of August, 2025 AEST
Key Points
Revenue down 51.7% to $196,875 USD
Net loss after tax increased 91.6% to $13.14 million USD
Equity raise of $42.8 million USD completed in March 2025
Expansion of European sales team and clinical trial costs increased expenses
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imricor Medical Systems (ASX:IMR)
OPEN ARTICLE